How semaglutide's mechanism of action drives weight loss

What the GLP-1 receptor actually does, and why semaglutide targets it

GLP-1 stands for glucagon-like peptide-1, a hormone your gut releases in response to eating. Its natural job is to tell the pancreas to release insulin, signal the brain that food has arrived, and slow the rate at which the stomach empties. The problem is that natural GLP-1 is broken down within minutes. Semaglutide is a synthetic analogue, chemically similar enough to slot into the same receptor, but structurally modified so the body's enzymes leave it largely intact. The result is a half-life of roughly a week, which is why a once-weekly injection is sufficient.

When semaglutide binds to GLP-1 receptors in the brain (specifically in the hypothalamus and brainstem areas that govern hunger) it damps down appetite signals. This is a central effect, distinct from the gut-level slowing. People taking it often describe meals feeling satisfying far sooner than before, or simply not thinking about food as much between meals. That appetite reduction, sustained over weeks and months, is the main driver of weight loss. You can read more about how this translates into real-world results on our semaglutide (Wegovy) treatment overview.

The mechanism by which semaglutide produces these effects also involves reduced glucagon secretion, which lowers the liver's glucose output. In people without diabetes this effect is modest at therapeutic doses, but it contributes to the stable blood-sugar environment that makes calorie reduction easier to sustain.

Gastric emptying, side effects, and the connection between them

Slowing gastric emptying is central to how semaglutide works, food sits in the stomach longer, prolonging the sense of fullness. It also explains why nausea is the most common early side effect. When the stomach empties slowly, its contents can feel unsettled, particularly after meals that are larger than usual or rich in fat. For most people this is most pronounced in the first few weeks of a new dose and settles as the body adjusts.

Other gastrointestinal effects follow the same logic: constipation (food moving slowly through the gut), diarrhoea or loose stools in some, burping, indigestion. None of this is the medicine misfiring, it is the mechanism working, with the gut adapting in real time. Practical steps like eating more slowly, reducing portion sizes, and avoiding very fatty meals tend to help considerably. How quickly semaglutide takes effect is a related question worth reading alongside this, because the timing of side effects tracks closely with when the medicine reaches its active concentration.

One interaction worth flagging here: because gastric emptying is slowed, the absorption of oral medicines taken at the same time may be reduced. The oral contraceptive pill is the most clinically relevant example for many patients, a prescriber will advise whether an additional contraceptive method is needed during the early weeks of treatment. The NHS England guidance on weight-management injections covers this point specifically.

How the action mechanism shapes who semaglutide is licensed for

Because semaglutide's weight-loss effect is driven by appetite suppression and metabolic signalling rather than, say, blocking fat absorption, it is licensed for adults whose weight is affecting their health, a BMI of 30 or above, or 27 or above alongside a weight-related condition such as high blood pressure, type 2 diabetes, or obstructive sleep apnoea. Lower thresholds apply for some ethnic backgrounds under UK guidance. The mechanism does not change depending on dose, but the degree of appetite suppression and weight reduction does: the licensed weight-management doses of semaglutide (2.4 mg weekly and, following MHRA approval in April 2026, a dedicated 7.2 mg pen) are considerably higher than the doses used in diabetes treatment.

This also explains why Ozempic (also semaglutide, but at a lower dose) is not licensed for weight management in the UK. The dose matters. Likewise, Rybelsus tablets (also semaglutide, but at 3 mg, 7 mg or 14 mg) are licensed for type 2 diabetes, not weight loss. The weight-management tablet formulation is Wegovy, which uses a different dose ladder, and if oral semaglutide is something you're researching, our page on the full scope of semaglutide's action covers these distinctions in more detail.

If you're at the point of deciding whether semaglutide is right for your situation, the right next step is a clinical assessment, not a comparison of mechanisms. BMI alone doesn't determine suitability; your medical history, current medicines and individual goals all matter. To see how treatment costs are structured and what's included, that context may also help you make a grounded decision before speaking to a prescriber.

Where semaglutide sits compared with other weight-loss medicines

The semaglutide action mechanism activates one receptor pathway: GLP-1. Tirzepatide, the active ingredient in Mounjaro, activates two (GLP-1 and GIP) which appears to produce greater average weight reduction in head-to-head evidence, though both medicines work through related appetite and metabolic signalling. Orlistat works entirely differently, blocking fat-digesting enzymes in the gut rather than acting on hunger centres in the brain.

Understanding these differences is less about picking a winner and more about recognising that different mechanisms suit different people. Semaglutide's clinical trial data is substantial, the STEP 1 trial, published in the New England Journal of Medicine, reported around 15% average body-weight reduction over 68 weeks at the 2.4 mg dose. That is a meaningful result, and it came from the mechanism described above: sustained, central appetite suppression combined with slower gastric emptying. You can explore more on the weight-loss treatment options page, or look at the detail on semaglutide's mode of action for a deeper look at the pharmacology. A prescriber, not a mechanism comparison, is the right person to help you decide which treatment fits.

If you'd like to speak to one of our clinical team, check your eligibility and start a free consultation, your answers are reviewed the same day by a GPhC-registered prescriber.